Bill > A02650

This bill aims to improve patient access to abuse-deterrent opioid medications by requiring insurance carriers and health plans to provide coverage for at least one abuse-deterrent opioid analgesic drug product per active ingredient. The bill defines abuse-deterrent opioid drugs as those approved by the FDA with labeling claims indicating their ability to deter or reduce abuse. Insurance carriers must ensure that cost-sharing for these medications does not exceed the lowest cost-sharing level for non-abuse-deterrent opioid drugs, whether brand name or generic. Additionally, the bill prohibits insurers from implementing prior authorization requirements that mandate the use of non-abuse-deterrent opioid drugs before allowing access to abuse-deterrent alternatives. The legislation also prevents insurers from increasing patient costs or creating disincentives for prescribers or dispensers to comply with these requirements. By addressing these coverage and access issues, the bill seeks to support efforts to combat opioid abuse by making abuse-deterrent medications more accessible and affordable for patients who need them. The law will take effect 120 days after becoming law and will apply to all insurance policies and contracts issued, renewed, or modified after that date.

Business and Industry

https://www.nysenate.gov/legislation/bills/2025/A2650